Patents Assigned to SpringWorks Therapeutics, Inc.
  • Patent number: 12011424
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: June 18, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 12011435
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: June 18, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 12011434
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: June 18, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11957662
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: April 16, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11951096
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: April 9, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11938116
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: March 26, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11925619
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: July 30, 2023
    Date of Patent: March 12, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11925620
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: March 12, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11884610
    Abstract: The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: January 30, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Jiping Liu, Ricky Wayne Couch, Peter Gregory Varlashkin, Mai Li, Yonghong Gan
  • Patent number: 11883375
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: June 14, 2023
    Date of Patent: January 30, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 11872211
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: January 16, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11844780
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: December 19, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Patent number: 11839595
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: December 12, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 11819487
    Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 21, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 11806321
    Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 11806322
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
  • Patent number: 11807611
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: November 7, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Publication number: 20230330047
    Abstract: The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 19, 2023
    Applicant: SpringWorks Therapeutics, Inc.
    Inventors: Kristin PATTERSON, Jiping LIU
  • Patent number: 11780800
    Abstract: The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: October 10, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Piero L Ruggiero
  • Publication number: 20230147121
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: November 21, 2022
    Publication date: May 11, 2023
    Applicant: SpringWorks Therapeutics, Inc.
    Inventors: Kristin PATTERSON, Todd Webster SHEARER